Our Business
With the rapidly growing global metabolic disease epidemic, which includes diabetes and obesity, there is a significant need to bring safer, more effective medications to physicians and patients world-wide. InteKrin’s business strategy, under the guidance of InteKrin’s experienced Management Team and world-class Scientific Advisory Board and Board of Directors , is to build a robust portfolio of high-potential products through in-licensing clinical-stage therapeutic candidates to meet the growing patient needs. The InteKrin team uses its capabilities to rapidly and effectively shepherd these therapeutic candidates through critical development stages to de-risk them and maximize their commercial potential. Read More
Recent News
InteKrin Therapeutics Announces
$20 Million Series C Financing
Los Altos, California--(PR Newswire) InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity today announced it has completed the first close of a Series C venture financing for $18.25 million. The financing was led by Skyline Ventures of Palo Alto, CA and Managing Director David Lowe Ph.D. of Skyline will join InteKrin’s Board of Directors. Existing major investors Sofinnova Ventures and OrbiMed Advisors also significantly participated, as did other earlier investors. The Company anticipates a second close of the Series C bringing the total for the round to $20 million. Read More